GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Archived. This submission is more than a year old. Votes and new comments are closed, and some of the advice in it may have been superseded — check the community wiki for the current version.
2.1k
c/tirzepatide·posted 2 years ago by u/mod_cold_room

[Question] how do you actually verify GIP

Question Long Haul ×4 Cold Box ×2

Asking properly rather than in a comment on somebody else’s thread: how do you actually verify GIP.

Vials and pens carry the same molecule; what differs is fill volume, device tolerance and whether you are doing your own arithmetic. Neither is inherently more accurate.

Went 10 to 12.5 on the calendar and had the worst fortnight of the whole run. Dropped back to 10 and everything settled.

The distribution matters more than the mean. In the trial population the interquartile spread was wide enough that two honest people can have completely different runs on the same arm.

Not medical advice, obviously, and nothing here is approved for human use. One person with a spreadsheet.

3,038 up / 945 down76% upvoted23 commentsid 15e5st26 Oct 2023

23 comments

7 in this archive, depth 3

best — the order this archive was captured in

u/dario_stanescu170 points·2 years ago

SURMOUNT-1 ran 72 weeks with the top arm around 21% mean body weight change. SURPASS is the diabetes programme and reports glycaemic endpoints, so quoting the two interchangeably is a category error.

replysharereportpermalink
u/incretin_ivyMOD85 points·2 years ago

Left up, flair changed to Discussion. It is an opinion post and that is fine as long as it is labelled.

replysharereportpermalink
u/mod_cold_roomOPmod · c/coldchain48 points·2 years ago·edited

That percentage is body weight change, not body fat. Different measurement, and the distinction gets lost every time.

replysharereportpermalink
[removed]62 points·2 years ago

[removed by moderator]

replysharereportpermalink
load more comments (2) →
u/gentle_correctionnice about it113 points·2 years ago·edited

Disagree with the conversion table. There is no validated equivalence between the two molecules and posting one as though there is does real damage.

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/tirzepatide

Tirzepatide-specific discussion: the dual-agonist pharmacology, the 2.5 → 15mg ladder, the appetite profile people describe as different from semaglutide, and the SURMOUNT/SURPASS trial programme. Comparisons with semaglutide are welcome as long as they are specific about dose equivalence being unknown.

187kmembers
130submissions
Aug 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/tirzepatide rules
  1. "Tirz is better than sema" needs a comparator dose or it is a vibe, not a claim.
  2. Vial-splitting and self-compounding discussion stays in c/reconstitution.
  3. No pen-cracking tutorials. Discussing that people do it is fine; instructions are not.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.